Delcath Systems (DCTH) obtains approval in Australia for its Generation Two Hepatic Chemosat...

|About: Delcath Systems, Inc. (DCTH)|By:, SA News Editor

Delcath Systems (DCTH) obtains approval in Australia for its Generation Two Hepatic Chemosat Delivery system for for administering high doses of chemotherapy. The authorization in the country, where the market is worth $50M-$70M, adds to the EU's CE mark. Delcath is still waiting on the FDA. (PR)